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Abstract 
Background: In discrete-choice experiments (DCEs), respondents are presented with 
a series of scenarios and asked to select their preferred choice. In clinical decision making, 
DCEs allow one to calculate the maximum acceptable risk (MAR) that a respondent is willing 
to accept for a one-unit increase in treatment efficacy. Most published studies report the 
average MAR for the whole sample, without conveying any information about heterogeneity. 
For a sample of psychiatrists prescribing drugs for a series of hypothetical patients with 
schizophrenia, this article demonstrates how heterogeneity accounted for in the DCE modelling 
can be incorporated in the derivation of the MAR. Methods: Psychiatrists were given 
information about a group of patients’ responses to treatment on the Positive and Negative 
Syndrome Scale (PANSS) and the weight gain associated with the treatment observed in a 
series of 26 vignettes. We estimated a random parameters logit (RPL) model with treatment 
choice as the dependent variable. Results: Results from the RPL were used to compute the 
MAR for the overall sample. This was found to be equal to 4%, implying that, overall, 
psychiatrists were willing to accept a 4% increase in the risk of an adverse event to obtain a 
one-unit improvement of symptoms – measured on the PANSS. Heterogeneity was then 
incorporated in the MAR calculation, finding that MARs ranged between 0.5 and 9.5 across 
the sample of psychiatrists. Limitations: We provided psychiatrists with hypothetical 
scenarios, and their MAR may change when making decisions for actual patients. 
Conclusions: This analysis aimed to show how it is possible to calculate physician-specific 
MARs and to discuss how MAR heterogeneity could have implications for medical practice. 
  
INTRODUCTION 
The practice of evidence-based medicine involves a judicious combination of clinical 
expertise with the best available external clinical evidence from systematic research.1,2 
However, this dynamic process also requires a continuous re-appraisal of the patient’s 
condition and the expertise to revise a plan when the treatment benefits decline or when the 
treatment is not working as anticipated.3 For instance, clinicians must judge whether a patient 
is responding to treatment and often have to trade off the risks and benefits of different 
treatment options. Prescribing a treatment with risks that the patient is not willing to tolerate 
may result in poor treatment adherence and low patient satisfaction.4 It is therefore important 
to understand whether these trade-offs vary significantly across clinicians, which could, in turn, 
result in unacceptable outcome variations and inequities in care.  
Discrete-choice experiments (DCEs) have become widely employed to investigate 
patient and clinician preferences for different treatment options.5–8 In general a DCE survey 
involves presenting respondents with a series of choices between two or more alternative 
hypothetical treatments that vary on a range of attributes (characteristics of the treatment such 
as efficacy, benefits, and risks) and their levels and asking respondents to indicate their 
preferred choice.9  
Additionally, in estimating preference weights for different treatment characteristics, 
DCEs allow researchers to investigate how patients or clinicians trade off the risks and benefits 
of treatment. In two previous articles,10,11 we investigated what thresholds psychiatrists use 
when determining whether a patient is responding to treatment and whether psychiatrists were 
influenced by the patient’s genotype when recommending a treatment.  However, DCEs also 
enable the researcher to derive a marginal rate of substitutions between positively perceived 
attributes (such as benefits from a treatment) and negatively perceived attributes (such as costs 
or risks of adverse events linked to a treatment). Specifically, this article focusses on how to 
retrieve the maximum acceptable risk (MAR) that a psychiatrist is willing to accept in exchange 
for a one-unit increase in a benefit associated with the treatment.12 In this case, MAR represents 
the highest risk of an adverse event that a psychiatrist perceives would equal the benefits of 
prescribing the treatment.  
Every clinician has a specific MAR threshold, which may differ from that of his or her 
colleagues. However, most studies only focus on the overall average MAR for the sample, 
without informing the reader about this possible heterogeneity across clinicians, even though 
the typical modelling approach adopting a random parameters logit (RPL) model accounts for 
it.13–15 This study presents two methods widely used in preference analysis applied to other 
fields such as transportation and environmental economics to incorporate preference 
heterogeneity when computing marginal rates of substitution (e.g., MAR). We demonstrate this 
using data from a previous study with a sample of psychiatrists10,11 in which we aim to explore 
the extent of MAR heterogeneity across our sample of psychiatrists clinicians when prescribing 
treatments to their patients. The idea is to exploit the outcome from the RPL model, which 
allows us firstly to derive the unconditional distributions for each parameter – and therefore 
the MAR – and secondly to retrieve individual posterior estimates conditional to the sequence 
of choices observed for each individual psychiatrist in the sample. Finally, some of the 
implications for clinical practice and decision making are briefly discussed. This new study 
uses the same data set that was used in two previous publications.10,11 
METHODS 
Setting and study procedure 
The study was developed following good DCE research practice to understand how 
psychiatrists evaluate different options to treat schizophrenia and to explore the trade-offs they 
are willing to accept between benefits and risks of adverse events.16 The survey instrument was 
developed and pretested with practising psychiatrists to identify the appropriate attributes and 
levels to be used in a series of vignettes and to construct realistic choice tasks. The protocol for 
the study was approved by the Queen’s University School of Psychology ethics committee, 
and each respondent provided written informed consent.  
Once the survey instrument was ready for fielding, we used a convenience sample 
including all psychiatrists who attended their monthly continuous professional development 
training meetings in three different hospitals across Northern Ireland. Sample size was dictated 
by the planned meetings but allowed us to interview psychiatrists in person, enhancing data 
quality and control over the experiment.  
During data collection, members of the study team conducted both pre-test and final 
interviews in person. This allowed the researchers to explain the task if required, without 
leading the participants. In total, 70 psychiatrists were invited to participate in the study. They 
were asked to judge a series of hypothetical patient vignettes and rate their confidence in each 
judgement. One declined to participate, and two did not provide useable data. Therefore, the 
final sample included 67 psychiatrists. More than half (59%) were male, most (64%) had 
completed their specialist training, and the average years of clinical experience in their 
specialty was 10 years (SD = 7.19 years). 
Materials 
We recently reported on how we developed a series of 26 vignettes10,11 constructed to 
depict a patient’s pre- and post-treatment score on the positive sub-scale of the Positive and 
Negative Syndrome Scale (PANSS). The attributes and levels were determined with the help 
of two practising psychiatrists (Francis O’Neill and Joe Kane). See Figure 1 for an example of 
the vignette. The positive sub-scale contains seven questions relating to the positive symptoms 
of schizophrenia, such as hostility and delusions. Each question is scored on a scale of 1 
(symptom absent) to 7 (symptom extreme). Each respondent’s pre-treatment score on the 
PANSS was anchored at 42, indicating severe symptoms before any treatment. Psychiatrists 
were informed of (1) the patient’s change score on the PANSS (range 3-26); (2) whether the 
patient had a hyper-responsiveness genotype, indicating a hyper-responsiveness to treatment 
(dummy coded as 0 if hyper-responsiveness genotype was not present and 1 if hyper-
responsiveness genotype was present); (3) the number of anticipated acute treatment days in 
hospital (17-45 days); and (4) the risk of a 10 kg weight gain associated with the treatment 
(range 30%-70%).  
[Table 1 about here] 
Psychiatrists were asked to choose which of two treatments they would be willing to 
prescribe to the patient. Participant information sheets, participant informed consent forms, and 
a sample survey instrument are included in Appendix 1.  
The DCE experimental design was developed using a commonly used D-efficient 
algorithm to construct a fractional factorial experimental design as implemented in NGENE 
software.17–19 We used a semi-Bayesian design, since we applied prior information to build the 
design but did not update the priors after surveying several clinicians.20 An efficient design will 
have a “small” variance-covariance matrix, and D-efficiency is one measure that can be used 
to compare the relative efficiency of one experimental design with another. D-efficiency ranges 
between 0 and 100, and higher D-efficiency scores indicate that a particular design is better 
able than another to capture the trade-offs among attribute levels required to estimate the 
preference model.18  
[Figure 1 about here] 
Statistical analysis 
Preference data were analysed by estimating an RPL model, with treatment choice as 
the dependent variable and the attributes presented in the DCE as independent variables, 
employing normal distributions to accommodate preference heterogeneity for each attribute. 
The RPL model has been extensively applied in health preference assessment as it 
allows for heterogeneity across the respondents’ preferences.16,21 Generally, most DCE studies 
that have focussed on health preference assessment or medical decision making report the mean 
value of the preference weights – i.e., only reporting the mean of the distribution estimated in 
the RPL model. Following this trend, we firstly calculate an average MAR across all the 
psychiatrists by dividing the estimated coefficient for the change score on the PANSS by the 
estimated coefficient for the risk of gaining weight. The negative of this ratio is the average 
MAR of weight increase for a one-unit improvement in the PANSS.  
However, this average MAR does not account for preference heterogeneity, even if it 
is retrieved from the RPL model. A second option is to account for the heterogeneity within 
the RPL model by employing the estimated normal distribution in the computation of the MAR. 
This can be accomplished with two approaches: (1) by deriving an unconditional distribution 
based on the estimated mean and standard deviation of both the symptom score and the risk of 
weight gain or (2) by estimating a specific MAR for each psychiatrist by computing individual 
posterior parameters conditional on the sequence of their choices and the estimated normal 
distribution for the relevant parameters.  
Following the former approach, implemented through Monte Carlo sampling, we drew 
50,000 times from the estimated normal distributions of the change score and the risk, 
computing the ratios, and we then ordered and plotted the results from the lowest to the highest 
MAR. This exploits the ability of the RPL to accommodate heterogeneity; however, it does not 
allow the researcher to fully use the information contained in the sequence of choices that each 
respondent made. Indeed, the RPL model facilitates the computation of individual-specific 
preferences by deriving individuals’ conditional parameter distribution based on their 
choices.22–25 Those choices can be considered prior knowledge of the individual preferences, 
and therefore it is possible to invoke Bayes’ theorem to derive the expected posterior values of 
the individual parameters given the observed sequence of their choices: 
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where ߚመ௡ is the individual vector of parameters for respondent n for the observed 
sequence of choices, r denotes the generic draw of a random coefficient, and R denotes the 
total number of draws (50,000 in this case). We consider this method particularly suitable to 
our sample, given the long series of choices presented to the physicians.  
The MAR is then computed as the reciprocal of the ratio of the benefit (change score) 
and the risk parameters. In the results section, we present all the options depicted above and 
we discuss some differences. Statistical analysis was conducted in Biogeme version 2.3 and, 
for comparison, with STATA version 12. Individual posterior conditional parameters were 
computed in R version 3.4 (syntax code is included in Appendix 2). 
RESULTS 
Results from the RPL model are highlighted in Table 1. For each attribute, the model 
estimates a mean and a standard deviation of the normal distribution assumed to accommodate 
preference heterogeneity. So, for example, the normal distribution associated with the change 
score on the PANSS resulted in a mean estimate of 0.439 and a standard error of 0.190. For 
every decrease of one unit in symptoms on the PANSS, psychiatrists were significantly more 
likely to recommend the associated treatment, with a relatively small but highly significant 
heterogeneity. Conversely, for every increase of one unit in weight gain or extra days in 
hospital associated with the treatment, psychiatrists were less likely to recommend the 
treatment. 
Using the mean estimate for change score and risk of weight gain from the RPL model, 
we first estimated an average MAR. In this case, the MAR was 4.06, implying that, overall, the 
psychiatrists were willing to accept a 4% increase in the risk of the patient gaining 10 kg of 
weight to obtain a one-unit decrease in symptoms as measured by the PANSS.  
[Table 2 about here] 
Our next step was to generate an unconditional distribution of the MAR using the 
results (both mean and standard deviation) from the RPL model in Table 1. This allows us to 
better characterise the extent of the heterogeneity in the sample. As can be observed in Figure 2, 
unconditional MAR estimates based on the normal distribution, estimated with the RPL model, 
range between minus and plus infinity, a direct consequence of the assumption of a normal 
distribution for preference heterogeneity. The distribution reported in Figure 2 shows a MAR 
that varies across the sample between −2 and 18 and above (due to the shape of the normal 
distribution, the figure includes extreme values). 
[Figure 2 about here] 
The results are richer when we fully utilise the entire sequence of choices that each 
psychiatrist made when evaluating the 26 vignettes. Indeed, it is possible to retrieve the 
posterior conditional parameters for each decision maker using Bayes’ theorem (as described 
previously). As illustrated in Figure 3, using the choices made by each clinician, we retrieved 
the individual MARs conditional on each clinician’s pattern of choices. Inspection of Figure 3 
highlights a narrower range of MAR across respondents compared with the reported 
unconditional distribution in Figure 2. Nevertheless, the physicians most averse to risk had a 
MAR of about 2, while the least risk-averse psychiatrists had a MAR of about 10. 
[Figure 3 about here] 
DISCUSSION 
DCEs are increasingly used to assess preferences and to help understand how patients 
and clinicians trade off the risks and benefits associated with different treatment options15. 
DCEs also permit the estimation of the MAR that a decision maker might tolerate to gain a 
one-unit increase in treatment benefit26. However, in many previous studies where it has been 
estimated in an RPL, the derived MAR represents the average risk that respondents are willing 
to accept, ignoring the possibility that decision makers may make different benefit-risk trade-
offs.27 Thus our aim was to highlight a method that could be used to understand the extent of 
MAR variation across samples of decision makers. We have demonstrated a substantial 
variation in MARs across a sample of psychiatrists in one specialty in one region of the United 
Kingdom.  
In our analysis, we estimated an RPL model to analyse the psychiatrists’ preferences 
for different treatments for patients with schizophrenia. We used the results to compute the 
MAR at sample level and at individual level. Firstly, we looked at the mean estimate for benefit 
(change score on the PANSS) and risk of the treatment (probability of 10 kg weight gain) to 
compute an overall average MAR for the sample, finding a MAR of about 4%, implying that, 
overall, psychiatrists were willing to accept a 4% increase in the risk of adverse events to obtain 
a one-unit decrease in symptom score. (The remaining attributes were analysed in our previous 
articles.)10,11 This approach is often presented in the literature because it is simple to describe 
and directly computed from the outputs of the model. However, results from the RPL model 
are much richer as they consider the entire sequence of choices and the heterogeneity across 
clinicians. Therefore, we argue that researchers who assume heterogeneity in preferences (and 
estimate an RPL model as a consequence) should at least explore the consequences on the 
MAR of including such heterogeneity in the MAR calculation.  
We present two established methods to retrieve MAR incorporating preference 
heterogeneity: by deriving an unconditional distribution based on the estimated mean and 
standard deviation of both change score on the PANSS and the risk of weight gain and by 
computing individual posterior-based MAR for each psychiatrist conditional on the sequence 
of their choices and the estimated normal distribution for the relevant parameters. The two 
methods retrieve similar patterns of MAR across the sample, with slightly different outputs 
but, at least in this case, similar clinical implications. Once the three methods are used to 
explore MAR and sample heterogeneity, selecting the best representation depends on the aims 
of the study and the research questions and remains an empirical question. In our case, we think 
the MAR based on the individual parameters best addresses our question. Overall, we find that 
physicians in this sample have an individual MAR that ranges between 0.5 and 9.5 
These results have some important clinical implications. Champions of evidence-based 
medicine often advocate for a reduction in unexplained and unjustified variations in clinical 
care.2 Though our study focussed on the judgement of response to treatment, this is critical to 
decisions to continue with an evidence-based treatment, and in such cases, decisions must 
balance the perceived benefits and risks. Whereas many conceptual models of treatment 
thresholds are based on perceived benefits and expected utility, equally valid threshold models 
account for anticipated regret attendant on the risk of treatment.28 Indeed, these hybrid models 
predict that the variation in the decision-making styles of clinicians, attendant on their varying 
benefit-risk trade-offs, is consonant with a duel process model of decision making.29  
Several previous studies have shown a discordance between the MARs elicited from 
clinicians and those from patients.30 Both are important to personalised medicine. If a patient 
is not willing to tolerate the risks associated with a treatment, this may potentially affect 
treatment adherence4 and may lead to the inefficient allocation of health resources.31 
Furthermore Pravettoni et al. have argued that a “P4” paradigm (predictive, personalised, 
preventive, and participatory) for precision medicine is inadequate if it does not also consider 
individual psychology, advocating instead for a “P5” approach that accounts for the way 
patients may make differing judgements of risk and benefits.32 A similar perspective is offered 
by Rogowski et al. who have argued that while a greater research effort has so far gone into 
uncovering the physiological ways to personalise medicine (with genotypes and biomarkers), 
an equally valid approach is to reveal patient preferences and their benefit-risk tolerability 
thresholds elicited through DCEs.33 Though our own study focussed only on the clinicians’ 
thresholds, we recognise that it might be problematic to design vignettes for valid interpretation 
by patients with psychosis.  
Our study does have some limitations.10,11 For instance, we only looked at the MARs 
of psychiatrists, and future research is warranted to assess the MARs of clinicians who practice 
in other areas of medicine. We asked psychiatrists to assess a hypothetical patient only once, 
whereas in routine clinical practice, psychiatrists often see patients on many occasions, with 
supplementary information also being used for clinical assessments. Additionally, we did not 
explicitly tell psychiatrists how long each patient was taking their treatment, which may have 
influenced the psychiatrists’ MAR. Finally, in an ideal study, and following good research 
practice for DCE, the survey instrument should be focussed and only include one research 
question. However, to maximise the information gained from this study, we addressed several 
related research questions in our survey instrument (e.g., when do psychiatrists perceive a 
patient is responding to a treatment, how do they consider the information when making 
treatment decisions, and which trade-offs are they willing to accept), and it would not be 
possible to reach this sample for a second study to address the excluded research questions. 
This is not uncommon in social science, but we recognise it as a limitation in some occasions.  
The aim of the present article was to show how individual clinicians’ specific DCE 
parameters can be estimated for the MAR. In some contexts, there may be good reasons for 
why clinicians’ or patients’ MAR may vary. Risk perception and risk aversion traits have been 
associated with several other psychological characteristics that were not measured in our study. 
If a P5 model for personalised medicine gains traction, they merit exploration in future research 
to see how they might relate to individual MARs. In summary, we have shown how it is 
possible to estimate a MAR for individual clinicians and have demonstrated a substantial range 
of MARs for clinicians in one region. Understanding clinician and patient preferences as 
reflected in individual MARs has implications for personalised medicine, for it is essential that 
physicians and patients share a common understanding of the risks and benefits associated with 
treatment.  
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FIGURES 
 
Figure 1. Participants had to choose judge whether they believed the patient was responding 
to treatment, based on the change score on the PANSS. The coefficients for change score on 
the PANSS and the percentage probability of weight gain were used to derive the average and 
individual maximum acceptable risks (MARs). 
 
  
  
 
Figure 2. Line graph showing the unconditional distribution of MAR across the sample 
drawing from the distribution reported in the model’s estimates. The draw from the 
distribution are displayed in increasing order of MAR instead plotted as a Kernel distribution, 
for simpler comparison with Figure 3. 
 
 
 
  
TABLES 
Table 1. Attributes and levels 
Attributes Levels 
PANSS change score  Continuously ranging from 3 to 26 points 
Patient have a hyper-responsiveness 
Genotype 
 
 Yes 
 No 
Number of anticipated acute 
treatment days in hospital 
 
 Continuously ranging from 17 to 45 days 
Risk of a 10kg weight gain 
associated with the treatment 
 
 Continuously ranging from 30% to 70% 
  
Table 2. Random parameters logit with treatment choice as the dependent variable (N = 67, 
obs. = 1735) 
*P <.001, **P<.0001, σ = standard deviation (SD) of the normal distribution. 
Note: Genotype is a dummy coded variable equal to 1 if hyper-responsiveness genotype was 
present, zero otherwise. No hyper-responsiveness genotype is the reference category.  
± Coefficient refers to a one unit increase in the independent variable, e.g., a one unit increase 
in acute treatment days in hospital associated with the treatment. 
Variable Estimation Standard Error 95% confidence interval 
   Lower bound Upper bound 
PANSS change score± 0.439** 0.04 0.3606 0.5174 
 
σ  PANSS change score  
 
 
0.190** 
 
0.03 0.1312 0.2488 
Genotype 
 -0.247 0.17 ‐0.5802 0.0862 
σ  Genotype 
 1.020** 0.17 0.6868 1.3532 
Number of acute 
treatment days in 
hospital± 
 
-0.106** 0.01 ‐0.1256 ‐0.0864 
σ  Number of  acute 
treatment days in 
hospital 
 
0.041* 0.02 0.0018 0.0802 
Risk of weight gain 
associated with 
treatment± 
 
-0.108** 0.01 ‐0.1276 ‐0.0884 
σ  Risk of weight gain 
associated with 
treatment 
 
0.038** 0.01 0.0184 0.0576 
K (number of 
parameters) 8 
Log likelihood -533.073 
